The estimated Net Worth of Antonio Gualberto is at least $7.12 Million dollars as of 10 July 2019. Antonio Gualberto owns over 18,000 units of Kura Oncology Inc stock worth over $7,116,503 and over the last 5 years Antonio sold KURA stock worth over $0.
Antonio has made over 1 trades of the Kura Oncology Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Antonio exercised 18,000 units of KURA stock worth $110,700 on 10 July 2019.
The largest trade Antonio's ever made was exercising 18,000 units of Kura Oncology Inc stock on 10 July 2019 worth over $110,700. On average, Antonio trades about 18,000 units every 0 days since 2019. As of 10 July 2019 Antonio still owns at least 357,973 units of Kura Oncology Inc stock.
You can see the complete history of Antonio Gualberto stock trades at the bottom of the page.
Antonio's mailing address filed with the SEC is C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO, CA, 92121.
Over the last 6 years, insiders at Kura Oncology Inc have traded over $16,903,587 worth of Kura Oncology Inc stock and bought 50,000 units worth $575,000 . The most active insiders traders include Faheem Hasnain, Troy Edward Wilson, and Mary T Szela. On average, Kura Oncology Inc executives and independent directors trade stock every 63 days with the average trade being worth of $626,260. The most recent stock trade was executed by Teresa Brophy Bair on 20 May 2024, trading 2,615 units of KURA stock currently worth $57,922.
at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.
Kura Oncology Inc executives and other stock owners filed with the SEC include: